Contact us

Support


ViiV Healthcare

The production of the Dolutegravir preparation which was developed by ViiV Healthcare to treat HIV will be localized in Russia. The drug will be produced by the Moscow-based Servier pharmaceutical plant.

24 August 2017
http://riaami.ru

Serdix of Russia started its integrated production of the first registration series of Tivicay® (INN Dolutegravir) by ViiV Healthcare within the framework of the partnership agreement for localization of production of the drug for HIV infected in Russia.

The Project Launch Memorandum was executed on 25 May 2016 within the framework of the annual forum hosted by the Science, Industrial Policy and Entrepreneurship Department of the Moscow Government with the capital city Mayor, Mr. Sergei Sobyanin, in attendance.

01 September 2016
http://www.pharmvestnik.ru/

British company ViiV Healthcare announced its intention to localize a drug for the treatment of human immunodeficiency virus (HIV) - Dolutegravir (active ingredient) in Russia. According to the representatives of both parties, the production will be launched at the facilities of Serdix, Russian subsidiary of French company Servier.

30 May 2016
Investor
3.7 mln
Moscow Region

Investor profile

ViiV Healthcare

Great Britain

Company's website: www.viivhealthcare.com

T: +44 (0)20 8380 6200

Private company

Contact: Dr Dominique Limet, Director General

ViiV Healthcare was established in 2009 and is an international company specializing in the treatment of HIV infections; the majority interest is owned by GSK, other two shareholders are Pfizer and Shionogi.

Subscribe to Newsletters

Email: